Masimo Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US5747951003
USD
142.26
0.07 (0.05%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Masimo Corp. stock-summary
stock-summary
Masimo Corp.
Pharmaceuticals & Biotechnology
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company's business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include non-invasive monitoring of blood constituents with an optical signature, optical organ oximetry monitoring, electrical, brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring. In addition, the Company has developed the Root patient monitoring and connectivity platform, the Radical-7 bedside and portable patient monitor, and the Radius-7 wearable wireless patient monitor. It offers Patient SafetyNet remote patient surveillance monitoring system, which allows patients to be monitored through a personal computer-based monitor or by care providers through their pagers, voice-over-Internet Protocol (IP) phones or smartphones.
Company Coordinates stock-summary
Company Details
52 Discovery , IRVINE CA : 92618-3105
stock-summary
Tel: 1 949 29770001 949 2977077
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 104 Schemes (57.52%)

Foreign Institutions

Held by 234 Foreign Institutions (19.71%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Joseph Kiani
Chairman of the Board, Chief Executive Officer
Dr. Steven Barker
Director
Mr. H Michael Cohen
Independent Director
Mr. Sanford Fitch
Independent Director
Sen. (Retd.) Thomas Harkin
Independent Director
Mr. Adam Mikkelson
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
371 Million
(Quarterly Results - Jun 2025)
Net Profit:
45 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 10,544 Million (Small Cap)

stock-summary
P/E

409.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.45

stock-summary
Return on Equity

5.63%

stock-summary
Price to Book

10.11